8-(1,3-Dimethylpyrazol-4-Yl)-1-(3-Fluoro-5-Methoxypyridin-4-Yl)-7-Methoxy-3-Methylimidazo[4,5-C]Quinolin-2-One

1 trials

Filter these 1 trials by condition, phase, country and more.

Open in Search →

1 Registered trials

0 Recruiting

1 Completed trials

1 Sponsors

8 Countries

Phase II

Phase II: 1

Sponsors using this IMP

Merck Healthcare KGaA 1

All trials

1 total

Tuvusertib Combined with Niraparib or Lartesertib in Participants with Epithelial Ovarian Cancer (DDRiver EOC 302) Ended

2024-511202-23-00 Phase II 8 countries Merck Healthcare KGaA

Showing 1–1 of 1 trials

← All drugs A–Z